<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00509418</url>
  </required_header>
  <id_info>
    <org_study_id>VIUNASH-07</org_study_id>
    <nct_id>NCT00509418</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Viusid in Patients With Nonalcoholic Steatohepatitis</brief_title>
  <official_title>Efficacy and Safety of Viusid, a Nutritional Supplement, in Patients With Nonalcoholic Steatohepatitis. A Randomized, Controlled and Open Label Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catalysis SL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catalysis SL</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate whether Viusid, a nutritional supplement, in
      combination with diet and exercise improve the histological results (steatosis,
      necro-inflammatory activity and fibrosis) in comparison with diet and exercise, during 24
      weeks of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The histological improvement (steatosis, necro-inflammatory activity and fibrosis) at 24 weeks (end of the treatment).</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alanine aminotransferase levels (end of the treatment), δ-glutamyltransferase levels (end of the treatment), Body weight, Body Mass Index, Waist circumference (end of the treatment) Insulin resistance (HOMA) (end of the treatment)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Viusid, a nutritional supplement, in combination with controlled diet and exercise</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Controlled diet and exercise</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Viusid</intervention_name>
    <description>Viusid, a nutritional supplement. Three oral sachets Daily 24 weeks</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Nutritional supplement</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hypocaloric Diet with controlled exercise</intervention_name>
    <description>Modified ADA diet in combination with controlled exercise daily 24 weeks</description>
    <arm_group_label>B</arm_group_label>
    <other_name>lifestyle modification</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological diagnosis of steatohepatitis (minimal histological criteria for
             steatohepatitis include steatosis involving at least 5% of hepatocytes, lobular
             inflammation, and/or fibrosis)

          -  Age between 18 and 70 years

          -  Ability to provide informed consent

          -  Absence of significant alcohol ingestion (weekly ethanol consumption of less than 40
             g)

        Exclusion Criteria:

          -  Presence of other form of liver diseases (viral or autoimmune hepatitis, drug-induced
             liver disease, metabolic and hereditary liver disease and α-1 antitrypsin deficiency)

          -  Pregnancy or lactation

          -  Decompensated cirrhosis

          -  Presence of secondary cause of NAFL such as medications that induce steatosis
             (corticosteroids, estrogens, methotrexate, amiodarone, tamoxifen and calcium channel
             blockers) and gastrointestinal bypass surgery

          -  Pharmacological treatment with some potential benefit on NAFL including
             ursodeoxycholic acid, vitamin E, betaine, pioglitazone, rosiglitazone, metformin,
             pentoxifylline or gemfibrozil

          -  Fasting glucose levels greater than 250 mg per deciliter (13.3 mmol per liter)

          -  Contraindication to liver biopsy

          -  Refusal to participate in the study

          -  Concomitant disease with reduced life expectancy

          -  Severe psychiatric conditions

          -  Drug dependence
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adelaida Rodríguez de Miranda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Gastroenterology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institute of Gastroenterology</name>
      <address>
        <city>Vedado</city>
        <state>Havana</state>
        <zip>10400</zip>
        <country>Cuba</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cuba</country>
  </location_countries>
  <reference>
    <citation>Vilar Gomez E, Gra Oramas B, Soler E, Llanio Navarro R, Ruenes Domech C. Viusid, a nutritional supplement, in combination with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. Liver Int. 2007 Mar;27(2):247-59.</citation>
    <PMID>17311621</PMID>
  </reference>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2007</study_first_submitted>
  <study_first_submitted_qc>July 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2007</study_first_posted>
  <last_update_submitted>January 9, 2009</last_update_submitted>
  <last_update_submitted_qc>January 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2009</last_update_posted>
  <responsible_party>
    <name_title>Eduardo Vilar Gómez</name_title>
    <organization>National Institute of Gastroenterology</organization>
  </responsible_party>
  <keyword>Nonalcoholic steatohepatitis</keyword>
  <keyword>Nonalcoholic Fatty Liver</keyword>
  <keyword>Nutritional supplement</keyword>
  <keyword>Diet</keyword>
  <keyword>Exercise</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

